Piqray 50 mg and 200 mg film-coated tablets
Sponsors
F. Hoffmann-La Roche AG, Oslo University Hospital HF, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Ospedale Pediatrico Bambino Gesu, BOOG Study Center B.V.
Conditions
Advanced solid tumorBreast cancerCancerDent 2 diseaseMetastatic breast cancerMultiple myelomaNon-Hodgkin lymphomaT-cell prolymphocytic leukemia
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Improving public cancer care by implementing precision medicine in Norway
A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Start: 2021-04-01Target: 6000Updated: 2026-01-22
SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor positive HER2 negative advanced breast cancer
Active, not recruitingCTIS2024-514965-20-00
Start: 2022-06-02Target: 130Updated: 2024-09-11
A no-profit, open-label, phase II pilot study on the efficacy and safety of
Alpelisib in patients with Dent 2 disease
(ALPEDENT study)
RecruitingCTIS2024-514196-17-00
Start: 2025-03-14Target: 4Updated: 2025-01-17
Impact of time of alpelisib administration, concomitant fasting and low carbohydrate diet on alpelisib toxicity and efficacy; a pilot randomized controlled phase IIb trial- ITACA
WithdrawnCTIS2025-521008-22-00
Target: 30Updated: 2025-02-27